EVI-1 Antibody

ELISA: EVI-1 Antibody [28100002]

Product Discontinued

EVI-1 Antibody Summary

• Immunogen: This antibody is specific for the N Terminus Region of the target protein.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: MECOM
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:250-1:2000
  • Western Blot 1:5000-1:20000
• Application Notes: Use in Immunohistochemistry reported in scientific literature (PMID:26834490).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20 mM Potassium Phosphate (pH 7.0), 0.15 M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for EVI-1 Antibody

• AML1-EVI-1 fusion protein
• AML1-EVI-1
• ecotropic viral integration site 1
• Ecotropic virus integration site 1 protein homolog
• EVI1
• EVI-1
• EVI1MDS1-EVI1
• MDS1 and EVI1 complex locus protein EVI1
• MDS1 and EVI1 complex locus protein MDS1
• MDS1 and EVI1 complex locus
• MDS1
• MECOM
• MGC163392
• MGC97004
• Myelodysplasia syndrome 1 protein
• myelodysplasia syndrome 1
• Myelodysplasia syndrome-associated protein 1
• oncogene EVI1
• PRDM3
• zinc finger protein Evi1

Background

EVI1 (ecotropic viral integration site 1) was originally identified as a gene located in the integration site of ecotropic retroviruses in the mouse genome that resulted in myeloid tumors. EVI1 is a zinc finger transcription factor that plays an important role in development and leukemogenesis. It is an oncogene that can have effects on cell proliferation, differentiation, and apoptosis. Chromosomal translocations involving EVI1 result in chronic myelogenous leukemia (CML). Alternate names for EVI1 include AML1-EVI-1 fusion protein, PRDM3, and MDS1-EV1.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for EVI-1 Antibody (28100002)(3)

Publications using 28100002

• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Hou A, Zhao L, Zhao F et al. Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme. Onco Targets Ther 2016-01-13 [PMID: 26834490] (IF/IHC)
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Review for EVI-1 Antibody (28100002) (1)

Average Rating: 3

(Based on 1 review)

We have 1 review tested in 1 species: Human.

reviewed by: Verified Customer ELISA Human 11/09/2018

Summary

• Application: ELISA
• Sample Tested: Serum and Plasma
• Species: Human
• Lot: T00659A02

Bioinformatics

• Gene Symbol: MECOM
• Entrez:
  • 2122(Human)
• Uniprot:
  • Q03112()